Achieve Life Sciences (ACHV)
(Real Time Quote from BATS)
$4.55 USD
-0.06 (-1.30%)
Updated Apr 29, 2024 01:36 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Achieve Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 27 | 41 | 33 | 15 | 17 |
Income After Depreciation & Amortization | -27 | -41 | -33 | -15 | -17 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3 | 2 | 0 | 0 | 0 |
Pretax Income | -30 | -42 | -33 | -15 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -42 | -33 | -15 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -42 | -33 | -15 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -27 | -41 | -33 | -14 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -27 | -41 | -33 | -15 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 19.83 | 10.59 | 8.12 | 2.72 | 0.41 |
Diluted EPS Before Non-Recurring Items | -1.50 | -4.00 | -4.08 | -5.42 | -39.80 |
Diluted Net EPS (GAAP) | -1.50 | -4.00 | -4.08 | -5.42 | -39.80 |
Fiscal Year end for Achieve Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.38 | 6.57 | 7.72 | 8.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.38 | -6.57 | -7.72 | -8.57 |
Non-Operating Income | NA | -0.30 | 0.25 | 0.19 | 0.16 |
Interest Expense | NA | 0.79 | 0.78 | 0.71 | 0.57 |
Pretax Income | NA | -5.48 | -7.11 | -8.24 | -8.99 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.48 | -7.11 | -8.24 | -8.99 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.48 | -7.11 | -8.24 | -8.99 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 21.17 | 21.13 | 19.05 | 17.92 |
Diluted EPS Before Non-Recurring Items | NA | -0.26 | -0.34 | -0.43 | -0.50 |
Diluted Net EPS (GAAP) | NA | -0.23 | -0.34 | -0.43 | -0.50 |